These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 12324628)

  • 1. Update on the role of topotecan in the treatment of recurrent ovarian cancer.
    Herzog TJ
    Oncologist; 2002; 7 Suppl 5():3-10. PubMed ID: 12324628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with topotecan in relapsed ovarian cancer.
    Herzog TJ
    Gynecol Oncol; 2003 Sep; 90(3 Pt 2):S3-7. PubMed ID: 13129489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
    Bookman MA; Malmström H; Bolis G; Gordon A; Lissoni A; Krebs JB; Fields SZ
    J Clin Oncol; 1998 Oct; 16(10):3345-52. PubMed ID: 9779711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging role of topotecan in front-line treatment of carcinoma of the ovary.
    Coleman RL
    Oncologist; 2002; 7 Suppl 5():46-55. PubMed ID: 12324633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized single-agents trials in recurrent epithelial ovarian cancer.
    Sessa C; Marsoni S
    Int J Gynecol Cancer; 2005; 15 Suppl 3():247-51. PubMed ID: 16343240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
    Bookman MA
    Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of topotecan for relapsed ovarian cancer in accordance with the National Institute for Clinical Excellence Guidance 2001: the Nottingham experience.
    Anand A; Chan SY
    Clin Oncol (R Coll Radiol); 2004 Dec; 16(8):543-8. PubMed ID: 15630848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan: a review of its efficacy in small cell lung cancer.
    Ormrod D; Spencer CM
    Drugs; 1999 Sep; 58(3):533-51. PubMed ID: 10493279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer.
    Morris R; Munkarah A
    Oncologist; 2002; 7 Suppl 5():29-35. PubMed ID: 12324631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
    Gronlund B; Hansen HH; Høgdall C; Engelholm SA
    Cancer; 2002 Oct; 95(8):1656-62. PubMed ID: 12365013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma.
    ten Bokkel Huinink W; Lane SR; Ross GA;
    Ann Oncol; 2004 Jan; 15(1):100-3. PubMed ID: 14679127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topotecan. A review of its potential in advanced ovarian cancer.
    Brogden RN; Wiseman LR
    Drugs; 1998 Oct; 56(4):709-23. PubMed ID: 9806112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
    Gordon AN; Tonda M; Sun S; Rackoff W;
    Gynecol Oncol; 2004 Oct; 95(1):1-8. PubMed ID: 15385103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum.
    Sehouli J; Stengel D; Oskay G; Blohmer J; Kaubitzsch S; Lichtenegger W
    J Obstet Gynaecol Res; 2003 Jun; 29(3):123-31. PubMed ID: 12841693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
    Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
    Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Topotecan: prospects for using it in combination therapy for ovarian carcinoma].
    Scarfone G
    Tumori; 1999; 85(6 Suppl 1):S12-5. PubMed ID: 10786195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
    Kollmannsberger C; Mross K; Jakob A; Kanz L; Bokemeyer C
    Oncology; 1999; 56(1):1-12. PubMed ID: 9885371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.